Pfizer has launched its biosimilar trastuzumab, Trazimera, in Spain. The biosimilar became available to Spanish patients with early and locally advanced or metastatic HER2-positive breast cancer and HER2-positive metastatic gastric cancer on April 1, 2019.
Pfizer has launched its biosimilar trastuzumab, Trazimera, in Spain. The biosimilar became available to Spanish patients with early and locally advanced or metastatic HER2-positive breast cancer and HER2-positive metastatic gastric cancer on April 1, 2019.
César A. Rodríguez, MD, of the department of medical oncology at the University Hospital of Salamanca, said in a statement that the biosimilar will increase access to innovative therapies; the availability of a lower-cost trastuzumab option will allow for the better management of resources, he said, allowing more people to be treated.
Miguel Angel Calleja, PharmD, head of pharmacy at the Hospital Virgen Macarena de Sevilla, added that, in addition to the biosimilar’s demonstrated efficacy and safety, the product provides an advantage because it can be stored without the need for a cold chain for a period of 3 months, thereby reducing hospital staff workload.
Trazimera was approved for marketing in the European Union in July 2018, making it the fourth biosimilar trastuzumab to receive the European Commission (EC)’s clearance, following Ontruzant, Herzuma, and Kanjinti; later, the EC approved Ogivri, the fifth EU biosimilar trastuzumab.
Trazimera has also been approved by the FDA; in March 2019, Trazimera became the fourth US-approved biosimilar trastuzumab, following Ontruzant, Herzuma, and Ogivri. However, no biosimilar trastuzumab products have yet launched in the United States.
Trazimera’s data package that led to approval included findings from the comparative clinical trial for the biosimilar, REFLECTIONS B327-02. The study found that, in patients receiving trastuzumab and paclitaxel as first-line treatment for HER2-positive metastatic breast cancer, the biosimilar showed similar efficacy, safety, immunogenicity, and pharmacokinetics (PK) to the EU-licensed reference drug. The study met its primary objective for equivalence in the objective response rate (ORR) for the biosimilar versus the reference, with the risk ratio of ORR of 0.940 (95% CI, 0.842-1.049) falling within the prespecified equivalence margin of 0.8 to 1.25.
A supplemental study of the biosimilar as neoadjuvant therapy in combination with docetaxel and carboplatin, REFLECTIONS B327-04, found no clinically meaningful differences between the biosimilar and the EU-licensed reference in terms of efficacy, safety, immunogenicity, and noninferiority in terms of PK.
No US launch date for the biosimilar has been disclosed.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
August 22nd 2024Alvotech reported $236 million in revenue for the first 6 months of 2024, a 10-fold increase from the same period the year prior. The new figures come after the company received its first 2 FDA approvals in 2024.